Lactate Dehydrogenase-to-Albumin Ratio (LAR) as a Prognostic Marker in Egyptian Patients with Advanced Classical Hodgkin Lymphoma | ||
| The Egyptian Journal of Hospital Medicine | ||
| Volume 100, Issue 1, July 2025, Pages 4441-4445 PDF (636.34 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2025.454577 | ||
| Abstract | ||
| Background: Classical Hodgkin lymphoma (cHL) is a malignancy with a high likelihood of successful treatment when detected at an early stage. In advanced-stage disease there is high rate of becoming refractory or developing relapse following first line treatment. Traditional factors for identifying high-risk HL patients are currently less predictive in the era of PET-adapted strategies and novel therapies. Objectives: This study aimed to evaluate LAR as a simple, low-cost laboratory prognostic marker in Egyptian patients with advanced cHL. Patients and methods: An open-label prospective study was conducted on 50 participants with stage III/IV cHL. Participants were assigned to have Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD). Univariate analysis of prognostic factors was done. LAR was calculated at baseline, and its predictive value for progression was assessed. Results: High LAR (>8) was significantly associated with disease progression (AUC=0.82, p<0.001). Participants with high LAR had shorter PFS (HR=2.8, 95% CI: 1.4–5.6, p=0.003). Conclusion: LAR is a promising prognostic bio indicator for determining high-risk individuals who may benefit from intensified therapy. | ||
| Keywords | ||
| Hodgkin Lymphoma; ABVD; LAR; PET/CT | ||
|
Statistics Article View: 71 PDF Download: 25 |
||
